alexa Understanding the Biology Behind the EGFR to Improve NSCLC Patients’ Treatment | OMICS International
ISSN: 1747-0862
Journal of Molecular and Genetic Medicine
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Understanding the Biology Behind the EGFR to Improve NSCLC Patients’ Treatment

Verlicchi A1 and Addeo A2*

1Department of Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

2Department of Oncology, Bristol Cancer Institute, Bristol, UK

*Corresponding Author:
Dr. Alfredo Addeo
Department of Oncology
Bristol Cancer Institute
Bristol, UK
Tel: +44117923 0000
E-mail: [email protected]

Received Date: August 9, 2017; Accepted Date: August 29, 2017; Published Date: September 1, 2017

Citation: Verlicchi A, Addeo A (2017) Understanding the Biology Behind the EGFR to Improve NSCLC Patients’ Treatment. J Mol Genet Med 11:286. doi: 10.4172/1747-0862.1000286

Copyright: © 2017 Verlicchi A, et al. This is an open-access article distributed under the terms of the creative commons attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Molecular and Genetic Medicine


Epidermal growth factor receptor (EGFR) is a member of the EGFR tyrosine kinase family, which consists of EGFR (erbB1/Her1), Her2/neu (erbB2), Her3 (erbB3) and Her4 (erbB4). HER receptors are ubiquitously expressed in various cell types, under homeostatic conditions, receptor activation is tightly regulated by the availability of ligands, which collectively form the EGF family.


Angiogenesis; Mutant tumours; Endothelial growth; Lung cancer


Several intra cellular pathways are tightly connected to the EGFR status, among them the two main signalling pathways activated by GFR include the ras/raF/meK/erK and the Pi3K/aKt axes; however, Src tyrosine kinases, PlCγ, PKC, and STAT activation and downstream signalling have also been well documented [1,2].

Literature Review

A direct link between EGFR activation and angiogenesis has been described. EGFR activation can contribute to the production of several proangiogenic factors in tumours, including VEGF and basic fibroblast growth factor [3,4].

Tumours that harbour activated oncogenes show often dependence on the prolonged activity of oncogenes and to the signalling pathways which makes them sensitive to drugs that target such pathways [5,6].

Several approaches have been developed to target the EGFR to interfere with EGFR-mediated cellular effects and the most utilised are monoclonal antibodies directed against the extracellular receptor domain and small-molecule compounds that interfere with intracellular EGFR tyrosine kinase activity [7].

Despite the initial response to such treatments virtually all the patients carrying an EGFR mutated progress. Several resistant mechanisms have been identified reflecting nonuniform response to treatment and a possible role for intratumor heterogeneity [8].

The response rate (RR) to the Tyrosine Kinase Inhibitors (TKIs) in patients with EGFR-mutated about 75%, which indicates a 25% of primary resistance to such treatments.

Several mutations, even within exons 18 to 21, the most common site for mutations, could be responsible for primary resistance to EGFR TKIs (e.g. small insertions or duplications in exon 20) [9]. In vitro and in vivo studies have shown that such mutations are less sensitive to EGFR TKIs than the exon 19 deletion and L858R mutants [10,11].

Another possible mechanism of resistance is the presence of other genetic lesions that affect signaling downstream of EGFR such as PI3K mutations, loss of PTEN and crosstalk between EGFR and insulin-like growth factor receptor 1 (IGF1R) [12-14].

A well-known mechanism of acquired resistance to TKIs in EGFR mutated non-small cell lung cancer (NSCLC) patients (incidence up to 50%) is the development of a second-site mutation in the threonine gatekeeper residue at position 790, T790M [15]. Interestingly in 2011 Rosell et al. found that in 35% of patients with EGFR mutated NSCLC the T790M mutation can be detected prior to EGFR TKI treatment [16].


In preclinical model of adenocarcinoma with exon 21 missense mutation (L858R) and exon 20 missense mutation (T790M) the combination of gefitinib with the vascular endothelial growth factor (VEGF) inhibitor bevacizumab was showed to inhibit tumour growth [17] and to overcome the primary resistance to TKIs. Level of signal transducer and activator of transcription 3 (STAT3) are increased almost immediately after starting erlotinib treatment in EGFR-mutant NSCLC cells [18]. Furthermore, STAT3 activation through IL- 6R and FGFR, in response to inhibition of an oncogenic kinase might significantly contributes to resistance of the cell population to drug treatment and consequently limits the efficacy of such agents [19]. It was also noted to play a key role in the interleukin 6 induced expression of VEGF in cervical cancer. VEGF was found to be inhibited by blocking STAT3 or by treatment with an anti-VEGF antibody [20]. IL-6 also play an essential role in activating the Scr family kinase and subsequently YES-associated protein 1 (YAP1) [21]. In a recent publication Chaib et al. [22] showed that Scr-YAP1 signalling limits EGFRTKI response, in conjunction with STA3, in lung cancer. This has strengthened the idea that EGRF TKI monotherapy is inadequate for NSCLC patients EGFR mutant. The co-activation of a broader network of signalling events limits the EGFR response.


Based on those findings combining EGFR-TKIs with VEGFneutralising antibodies might potentially delay or even inhibit the development of resistance driven by the interleukin 6–STAT3-VEGF pathway in EGFR-mutant NSCLC and represents a new therapeutic approach that is warranted clinical studies.

Conflict of Interest

Both the authors declare no conflict of interests.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 280
  • [From(publication date):
    September-2017 - Mar 20, 2018]
  • Breakdown by view type
  • HTML page views : 242
  • PDF downloads : 38

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version